SCHEMBL396909

SCHEMBL396909

CCCCCCCCCCCC(=O)N1CCCC1(O)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
TDP1 Q9NUW8 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
GNAI3 P08754 2/20 0.42
GNAI1 P63096 2/20 0.42
NAAA Q02083 2/20 0.40
FAAH O00519 1/20 0.40
GNAO1 P09471 1/20 0.40
GPR84 Q9NQS5 7/20 0.39
PPARG P37231 7/20 0.39
PPARD Q03181 7/20 0.39
PPARA Q07869 7/20 0.39
HDAC11 Q96DB2 5/20 0.39
TSHR P16473 4/20 0.39
PTPN1 P18031 3/20 0.39
ALDH1A1 P00352 2/20 0.39
TLR2 O60603 2/20 0.39
FABP4 P15090 2/20 0.39
SLC22A6 Q4U2R8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6516407 1.00 L3MBTL1 (0.47) L3MBTL1TDP1MEN1KMT2AGNAI3
SCHEMBL6717843 0.84 L3MBTL1 (0.44) L3MBTL1TDP1MEN1KMT2AGNAI3
SCHEMBL9632473 0.82 L3MBTL1 (0.42) L3MBTL1TDP1MEN1KMT2AGNAI3
SCHEMBL28142318 0.81 L3MBTL1 (0.46) L3MBTL1TDP1MEN1KMT2AGNAI3
SCHEMBL28384679 0.81 L3MBTL1 (0.46) L3MBTL1TDP1MEN1KMT2AGNAI3
SCHEMBL2544911 0.80 OPRM1 (0.34) ALDH1A1
Hydrochloric Acid SCHEMBL29663241 0.78 L3MBTL1 (0.50) L3MBTL1TDP1MEN1KMT2AGNAI3
SCHEMBL454182 0.75 S1PR1 (0.41) L3MBTL1TDP1MEN1KMT2A
SCHEMBL28772993 0.75 S1PR1 (0.41) L3MBTL1TDP1MEN1KMT2A
SCHEMBL10527688 0.75 S1PR1 (0.41) L3MBTL1TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12616730-B2 Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof MEDIHELPLINE CO., LTD (KR) 2026-05-05 US disclosed
EP-4074325-B1 COMPOSITION FOR PREVENTING, INHIBITING OR TREATING INFECTION OF CORONAVIRUS AMOREPACIFIC CORP (KR) 2024-07-31 EP disclosed
US-20240156888-A1 SKIN EXTERNAL COMPOSITION AND METHOD FOR PREPARING THE SAME AMOREPACIFIC CORPORATION (KR) 2024-05-16 US disclosed
US-20230127213-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF PARK, OK NAM (KR) 2023-04-27 US disclosed
US-20230103514-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF MEDIHELPLINE CO., LTD (KR) 2023-04-06 US disclosed
US-20230100173-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF MEDIHELPLINE CO., LTD (KR) 2023-03-30 US disclosed
US-11583560-B2 Immunomodulatory composition comprising lactobacillus-derived extracellular vesicles AMOREPACIFIC CORPORATION (KR) 2023-02-21 US disclosed
EP-4117700-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
EP-4117698-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
EP-4117699-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
EP-1793792-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA FOR PREVENTING AND TREATING BALDNESS DISORDERS AND SEBORRHEIC SKIN DISORDERS Helixir Co., Ltd. (KR) 2007-06-13 EP disclosed
US-20070122508-A1 Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease HELIXIR CO., LTD. (KR) 2007-05-31 US disclosed
WO-2007046636-A1 HERBAL COMPOSITION FOR PREVENTING AND IMPROVING BALDNESS KMSI CO., LTD (KR) 2007-04-26 WO disclosed
WO-2007007989-A1 LACTIC ACID BACTERIA CULTURE OF MUNG BEAN AND THE PREPARATION METHOD OF THE SAME, AND THE COSMETIC COMPOSITION COMPRISING THE SAME DOOSAN CORPORATION (KR) 2007-01-18 WO disclosed
WO-2006070978-A1 COMPOSITION FOR PROMOTING PRODUCTION OF HYALURONIC ACID CONTAINING KAEMPFEROL AND QUERCETIN AMOREPACIFIC CORPORATION (KR) 2006-07-06 WO disclosed
WO-2006043788-A1 COMPOSITION FOR PROTECTION AND IMPROVEMENT OF SKIN, OR REINFORCING SKIN BARRIER FUNCTION COMPRISING PHOSPHATIDYLSERINE DOOSAN CORPORATION (KR) 2006-04-27 WO disclosed
WO-2006016728-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA FOR PREVENTING AND TREATING BALDNESS DISORDERS AND SEBORRHEIC SKIN DISORDERS HELIXIR CO., LTD. (KR) 2006-02-16 WO disclosed
EP-1551433-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE Pangenomics Co., Ltd. (KR) 2005-07-13 EP disclosed
WO-2004096171-A1 SKIN WHITENING COSMETIC COMPOSITION COMPRISING THE EXTRACT OF MACHILUS THUNBERGII AND THE COMPOUNDS ISOLATED THEREFROM YEUNGNAM EDUCATIONAL FOUNDATION (KR) 2004-11-11 WO disclosed
WO-2004017982-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE PANGENOMICS CO., LTD (KR) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12616730-B2 Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof CUTA, VEGFA, MMP8 L3MBTL1 967/4885TDP1 1945/4885MEN1 4764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.